HDAC inhibition may combat resistance to anti-PD-1 therapy in patients with melanoma

(American Association for Cancer Research) A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed clinical responses in patients with melanoma that had progressed on prior anti-PD-1 treatment, according to results from the ENCORE 601 phase Ib/II clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news